TD Cowen Upgrades Stoke Therapeutics to Buy on Promising Updates for STK-001
Tuesday, 26 March 2024, 14:01
TD Cowen Upgrades Stoke to Buy on Positive Data for STK-001
TD Cowen has upgraded Stoke Therapeutics (STOK) to a buy rating following the release of updated Phase 1/2 data for their epilepsy drug candidate STK-001. The decision was influenced by the positive results observed in the trial, signaling potential growth opportunities for the company.
Key Points:
- Upgrade to Buy: TD Cowen shifts its rating for Stoke Therapeutics from hold to buy based on encouraging data.
- STK-001 Progress: The updated Phase 1/2 results indicate promising efficacy and safety profiles for the epilepsy drug.
This upgrade highlights the confidence in Stoke Therapeutics and their innovative approach to tackling neurological disorders, particularly epilepsy.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.